Bol, K.F.; Ellebaek, E.; Hoejberg, L.; Bagger, M.M.; Larsen, M.S.; Klausen, T.W.; Køhler, U.H.; Schmidt, H.; Bastholt, L.; Kiilgaard, J.F.;
et al. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. Cancers 2019, 11, 1489.
https://doi.org/10.3390/cancers11101489
AMA Style
Bol KF, Ellebaek E, Hoejberg L, Bagger MM, Larsen MS, Klausen TW, Køhler UH, Schmidt H, Bastholt L, Kiilgaard JF,
et al. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. Cancers. 2019; 11(10):1489.
https://doi.org/10.3390/cancers11101489
Chicago/Turabian Style
Bol, Kalijn Fredrike, Eva Ellebaek, Lise Hoejberg, Mette Marie Bagger, Mathilde Skaarup Larsen, Tobias Wirenfeldt Klausen, Ulrich Heide Køhler, Henrik Schmidt, Lars Bastholt, Jens Folke Kiilgaard,
and et al. 2019. "Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma" Cancers 11, no. 10: 1489.
https://doi.org/10.3390/cancers11101489
APA Style
Bol, K. F., Ellebaek, E., Hoejberg, L., Bagger, M. M., Larsen, M. S., Klausen, T. W., Køhler, U. H., Schmidt, H., Bastholt, L., Kiilgaard, J. F., Donia, M., & Svane, I. M.
(2019). Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. Cancers, 11(10), 1489.
https://doi.org/10.3390/cancers11101489